Teledyne e2v’s Emerald Gen2 GRENOBLE, France, Nov. 21, 2023 (GLOBE NEWSWIRE) — Teledyne e2v, a Teledyne Technologies [NYSE: TDY] company and global innovator of imaging solutions, announces Emerald™ Gen2, its new state-of-the-art CMOS image sensor family. Built on Teledyne e2v’s advanced imaging technologies, this new family delivers enhanced performance, making the new sensors ideal for […]
Read MoreUK’s newest challenger bank dedicated to supporting SMEs to be powered by nCino’s single platform LONDON and GLASGOW, Nov. 21, 2023 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced that Alba Bank (Alba) has made a significant step towards supporting the UK’s small- […]
Read MoreUK’s newest challenger bank dedicated to supporting SMEs to be powered by nCino’s single platform LONDON and GLASGOW, Nov. 21, 2023 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking for the global financial services industry, today announced that Alba Bank (Alba) has made a significant step towards supporting the UK’s small- […]
Read MoreBiosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) indicated for all conditions of reference medicine Humira®* Hyrimoz® HCF to launch progressively across Europe Hyrimoz® HCF strengthens well-established Sandoz biosimilar immunology portfolio in Europe Basel, November 21, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high […]
Read MoreCollaboration between the International Center for Genetic Disease and the Department of Health – Abu Dhabi, advances state-of-the-art precision medicine approaches and techniques, tailoring prevention, diagnosis, and treatment of diseases for the Emirati population. This collaboration encompasses three strategic pillars: clinical and translational research, capacity building and technology transfer, and commercialization. Boston, MA, Nov. 20, […]
Read MoreCollaboration between the International Center for Genetic Disease and the Department of Health – Abu Dhabi, advances state-of-the-art precision medicine approaches and techniques, tailoring prevention, diagnosis, and treatment of diseases for the Emirati population. This collaboration encompasses three strategic pillars: clinical and translational research, capacity building and technology transfer, and commercialization. Boston, MA, Nov. 20, […]
Read MoreCollaboration between the International Center for Genetic Disease and the Department of Health – Abu Dhabi, advances state-of-the-art precision medicine approaches and techniques, tailoring prevention, diagnosis, and treatment of diseases for the Emirati population. This collaboration encompasses three strategic pillars: clinical and translational research, capacity building and technology transfer, and commercialization. Boston, MA, Nov. 20, […]
Read MoreCollaboration between the International Center for Genetic Disease and the Department of Health – Abu Dhabi, advances state-of-the-art precision medicine approaches and techniques, tailoring prevention, diagnosis, and treatment of diseases for the Emirati population. This collaboration encompasses three strategic pillars: clinical and translational research, capacity building and technology transfer, and commercialization. Boston, MA, Nov. 20, […]
Read More